Rhythm Pharmaceuticals stock
RYTMNASDAQRhythm Pharmaceuticals, Inc., HealthcareISIN US76243J1051
46Score 46 out of 100, Weak
Price and trend
72 / 100
Price history
+12% in one yearThe chart shows daily closes over 9 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 13% above it.
Since November 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 69).
The price is 6.6% below its 52-week high. Largest decline in 9 years: 92% (January 2021 to May 2022).
Chart figures for advanced users
- SMA 50$96.68
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$97.19
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)69
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$75.82
- The lowest closing price of the last twelve months.
- Resistance$117.62
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Rhythm Pharmaceuticals, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $7.62B, is number 53 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $189.76M (up 45.8% year on year) and a loss of $196.54M.
- For fiscal 2026, analysts expect on average revenue of $326.76M (up 72.2%) and adjusted earnings per share of −$3.90.
Show more
- MEQIRI Score 46 out of 100 (Weak): rank 453 of 714 in Healthcare, median 53.
- Our model puts fair value at $211.85, with the price 47% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $320.94M, financial debt $106.18M.Stability 53
Weaknesses
- DilutionShare count up 47% since 2020.Capital allocation 9
- Loss-makingLoss of $193.81M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$127.43M over the last 12 months.Fundamentals 17
Its standout strengths are valuation and momentum, while fundamentals and capital allocation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
What lowers it
- price near its 52-week high
Valuation
Valuation signal
Possible value trapClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $151.32 and expensive above $353.08 (uncertainty high, based on the price swings of the past year).
Calculated with a cost of equity of 9.3%. At 10.3% the fair value would be $174.14, at 8.3% it would be $266.85.
Possible value trap: looks cheap, but score below 50, weak balance sheet.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 61% on the twelve months before. Revenue turned from negative at the start of the period to positive ($189.76M in the latest year).
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 90%, operating −101%, net −104%. Last 12 months: net −69%.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 25 Feb 2027in 105 days
- Last reported
- 3 Nov 2026EPS reported −$0.61 (expected −$0.71)above expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 38.4% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- −$3.90−32.2%
- Revenue
- $326.76M+2.6%
- Earnings per share
- −$0.89−38.4%
- Revenue
- $567.5M+1.4%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +7.7%R&D expense guidance midpoint cut by $20 million because of shifted timing while SG&A guidance is unchanged; cash is expected to fund operations for at least 24 months.
“SG&A guidance remains unchanged, while the midpoint of our R&D expense guidance has been reduced by $20 million as the timing of certain CMC activities related to RM-718 and bivamelagon has shifted from late 2026 to early 2027.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 4 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 8 insiders sold, $32.94M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Meeker David PSale
14 Sept 2026, President and CEO
- Shares
- 50,000
- Price
- $102.67
- Value
- $5.13M
- Smith Hunter CSale
31 Aug 2026, Chief Financial Officer
- Shares
- 62,774
- Price
- $105.46
- Value
- $6.62M
- Shulman JosephSale
13 Aug 2026, Chief Technical Officer
- Shares
- 5,079
- Price
- $119.75
- Value
- $608,210
Show 5 more
- Garfield AlastairSale
13 Aug 2026, Chief Scientific Officer
- Shares
- 7,763
- Price
- $117.57
- Value
- $912,703
- Lee Jennifer KaydenSale
13 Aug 2026, EVP, Head of North America
- Shares
- 75,834
- Price
- $117.38
- Value
- $8.9M
- Mazabraud YannSale
12 Aug 2026, EVP, Head of International
- Shares
- 57,000
- Price
- $116.15
- Value
- $6.62M
- Tetrault Lynn A.Sale
22 Jun 2026, Board
- Shares
- 37,000
- Price
- $100.32
- Value
- $3.71M
- German Christopher PaulSale
15 May 2026, Corporate Controller & CAO
- Shares
- 4,643
- Price
- $92.21
- Value
- $428,131
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Rhythm Pharmaceuticals
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 46
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- 10x GenomicsTXG $8.12B43
- AbivaxABVX.PA $8.11B36
- Twist BioscienceTWST $8.07B45
- Axsome TherapeuticsAXSM $7.85B32
- ImmunovantIMVT $7.64B45
- Bachem HoldingBANB.SW $7.3B58
- ImmunityBioIBRX $7.1B38
- Caris Life SciencesCAI $7.02B58
ETFs that hold Rhythm Pharmaceuticals
Held by 15 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Harbor Health Care UCITS ETF AccW311 | 4.78% | 0.89% | €11.61M |
| iShares Healthcare Innovation UCITS ETF2B78 | 0.64% | 0.40% | €1.49B |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.47% | 0.35% | €1.21B |
Show 5 more
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.22% | 0.30% | €2.17B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.22% | 0.30% | €4.22B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.08% | 0.43% | €2.48B |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.06% | 0.35% | €8.19B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.05% | 0.35% | €434.1M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Oct 2018)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.